Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Long-Term Deferred Tax (2018 - 2025)

Anika Therapeutics (ANIK) has disclosed Long-Term Deferred Tax for 8 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Deferred Tax fell 15.01% to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.3 million, a 15.01% decrease, with the full-year FY2024 number at $1.2 million, down 20.95% from a year prior.
  • Long-Term Deferred Tax was $1.3 million for Q3 2025 at Anika Therapeutics, roughly flat from $1.3 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $1.5 million in Q1 2023 to a low of $1.2 million in Q4 2024.
  • A 4-year average of $1.4 million and a median of $1.4 million in 2023 define the central range for Long-Term Deferred Tax.
  • Biggest YoY gain for Long-Term Deferred Tax was 3.37% in 2024; the steepest drop was 20.95% in 2024.
  • Anika Therapeutics' Long-Term Deferred Tax stood at $1.4 million in 2022, then rose by 2.76% to $1.5 million in 2023, then dropped by 20.95% to $1.2 million in 2024, then increased by 6.29% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Long-Term Deferred Tax are $1.3 million (Q3 2025), $1.3 million (Q2 2025), and $1.2 million (Q1 2025).